{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Ultragenyx Pharmaceutical Inc."},"Symbol":{"label":"Symbol","value":"RARE"},"Address":{"label":"Address","value":"60 LEVERONI COURT, NOVATO, California, 94949, United States"},"Phone":{"label":"Phone","value":"+1 415 483-8800"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older."},"CompanyUrl":{"label":"Company Url","value":"https://www.ultragenyx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Dennis Karl Huang","title":"Chief Technical Operations Officer & Executive VP"},{"name":"Emil D. Kakkis","title":"President, Chief Executive Officer & Director"},{"name":"Eric Crombez","title":"Chief Medical Officer & Executive Vice President"},{"name":"Samuel C. Wadsworth","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}